uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
Phase 1
Advertisement
Kither Biotech Doses First Patients in KIT2014 COPD Trial
TURIN, Italy — September 29, 2026 Kither Biotech Pty Ltd and Kither Biotech Srl announced that the first patients...
Cyprumed Oral Delivery Technology Enters Clinical Stage With MSD
INNSBRUCK, Austria — September 29, 2026 Cyprumed GmbH announced that MSD has initiated a Phase 1 clinical trial of...
Caspian Unveils KO-7246 Preclinical Diabetes Data at EASD
SAN DIEGO — September 29, 2026 Caspian Therapeutics and Kura Oncology announced new preclinical data for KO-7246, an investigational,...
HUTCHMED Initiates Global Phase I Trial of HMPL-A830
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 28, 2026 HUTCHMED (China) Limited announced the initiation of the...
Advertisements
C4 Therapeutics Presents Cemsidomide Biomarker Data in Multiple Myeloma
WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...
Altasciences Supports 4B Healthcare’s RhineX Clinical Advance
LAVAL, Québec — September 24, 2026 Altasciences announced that its formulation development, manufacturing and quality support for 4B Healthcare...
Adagene Gains NMPA Clearance for ADG138 IND
SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...
Viking Therapeutics Reports Positive VK2735 Weight Results
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
Polyrizon Enrolls First Patient in NASARIX U.S. Study
RAANANA, Israel — September 22, 2026 Polyrizon Ltd. announced enrollment of the first patient in its U.S. clinical study...
Advertisement
